Full text loading...
The impact of daily shifts on prostate IMRT dose distributions
1.W. A. Tomé and J. F. Fowler, “On cold spots in tumor subvolumes,” Med. Phys. 29, 1590–1598 (2002).
2.W. A. Tomé, S. L. Meeks, N. P. Orton, L. G. Bouchet, and F. J. Bova, “Commissioning and quality assurance of an optically guided three-dimensional ultrasound target localization system for radiotherapy,” Med. Phys. 29, 1781–1788 (2002).
3.F. Van den Heuvel, T. Powell, E. Seppi, P. Littrupp, M. Khan, Y. Wang, and J. D. Forman, “Independent verification of ultrasound based image-guided radiation treatment, using electronic portal imaging and implanted gold markers,” Med. Phys. 30, 2878–2887 (2003).
4.K. Langen, J. Pouliot, C. Anezinos, M. Aubin, A. Gottschalk, I. Hsu, D. Lowther, Y. Liu, K. Shinohara, L. Verhey, V. Weinberg, and M. Roach, “Evaluation of ultrasound-based prostate localization for image-guided radiotherapy,” Int. J. Radiat. Oncol., Biol., Phys. 57, 635–644 (2003).
5.W. A. Tomé, S. L. Meeks, N. P. Orton, L. G. Bouchet, and M. A. Ritter, “Patient Positioning in Radiotherapy using Optical Guided 3-D Ultrasound Techniques,” in New Technologies in Radiation Oncology, edited by W. Schlegel, T. Bortfelde, and A. Grosu (Springer, Berlin, in press).
6.D. Litzenberg, L. Dawson, H. Sandler, M. Sanda, D. McShan, R. Ten Haken, K. Lam, K. Brock, and J. Balter, “Daily prostate targeting using implanted radio-opaque markers,” Int. J. Radiat. Oncol., Biol., Phys. 52, 699–703 (2002).
7.A. Nederveen, H. Dehnad, U. van der Heide, R. van Moorselaar, P. Hofman, and J. Lagendijk, “Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials,” Radiother. Oncol. 68, 81–88 (2003).
8.E. Vigneault, J. Pouliot, J. Laverdiere, J. Roy, and M. Dorion, “Electronic portal imaging device detection of radio-opaque markers for the evaluation of prostate position during megavoltage irradiation: A clinical study,” Int. J. Radiat. Oncol., Biol., Phys. 37, 205–212 (1997).
9.A. Nederveen, U. van der Heide, H. Dehnad, R. van Moorselaar, P. Hofman, and J. Lagendijk, “Measurements and clinical consequences of prostate motion during a radiotherapy fraction,” Int. J. Radiat. Oncol., Biol., Phys. 53, 206–214 (2002).
10.M. Van Herk, P. Remeijer, C. Rasch, and J. Lebesque, “The probability of correct target dosage: Dose-population histograms for deriving treatment margins in radiotherapy,” Int. J. Radiat. Oncol., Biol., Phys. 47, 1121–1135 (2000).
11.H. Keller, W. A. Tomé, M. R. Ritter, and T. R. Mackie, “Design of adaptive treatment margins for non-negligible measurement uncertainty: Application to ultrasound-guided prostate radiation therapy,” Phys. Med. Biol. 49, 69–86 (2004).
12.R. R. Patel, N. P. Orton, W. A. Tomé, R. Chappell, and M. A. Ritter, “Rectal dose-sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer,” Radiother. Oncol. 67, 285–294 (2003).
13.P. Remeijer, E. Geerlof, L. Ploeger, K. Gilhuijs, M. van Herk, and J. Lebesque, “3-D portal image analysis in clinical practice: An evaluation of 2-D and 3-D analysis techniques as applied to 30 prostate cancer patients,” Int. J. Radiat. Oncol., Biol., Phys. 46, 1281–1290 (2000).
14.D. J. Brenner and E. J. Hall, “Fractionation and protraction for radiotherapy of prostate carcinoma,” Int. J. Radiat. Oncol., Biol., Phys. 43, 1095–1101 (1999).
15.J. Fowler and M. Ritter, “Is alpha/beta for prostate tumors really low?,” Int. J. Radiat. Oncol., Biol., Phys. 50, 1021–1031 (2001).
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Article metrics loading...